Postmenopausal hormone replacement therapy and venous thromboembolism

Gender Medicine

Volumn 2, Issue SUPPL. A, 2005, Pages

  Wu, Olivia ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Deep vein thrombosis; Estrogen; Hormone replacement therapy; Venous thromboembolism

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; GESTAGEN; PLACEBO;

AGING; ARTICLE; CANCER; CLINICAL TRIAL; CONFIDENCE INTERVAL; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG MEGADOSE; EMBASE; FEMALE; HIGH RISK PATIENT; HORMONE SUBSTITUTION; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; MEDLINE; MENOPAUSAL SYNDROME; META ANALYSIS; NATIONAL HEALTH SERVICE; OBESITY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; THROMBOPHILIA; UNITED KINGDOM; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

AGED; CONFIDENCE INTERVALS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MIDDLE AGED; ODDS RATIO; POSTMENOPAUSE; PULMONARY EMBOLISM; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; VENOUS THROMBOSIS; WOMEN'S HEALTH;

EID: 33645032251     PISSN: 15508579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1550-8579(05)80061-0     Document Type: Article

References (33)

1. Grady D Rubin SM Petitti DB et. al. Hormone therapy to prevent disease and prolong life in postmenopausal women Ann Intern Med. 117 1992 1016-1037
2. for the Writing group for the Women's Health Initiative Investigators Rossouw JE Anderson GL Prentice RL et. al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial JAMA 288 2002 321-333
3. Hillman JJ Zuckerman IH Lee E The impact of the Women's Health Initiative on hormone replacement therapy in a Medicaid program J Womens Health (Larchmt) 13 2004 986-992
4. Hulley SB Grady D The WHI estrogen-alone trial - do things look any better? JAMA 291 2004 1769-1771
5. Guldeline No. 19 Greer IA Walker ID Hormone replacement therapy and venous thromboembolism Royal College of Obstetricians and Gynaecologist 2004 1-9
6. Committee on Safety of Medicines. HRT Update on the risk of breast cancer and long-term safety Current Problems in Pharmacovigilence 29 2003 1-3
7. (SIGN Guideline 62) Scottish Intercollegiate Guidelines Network (SIGN) Prophylaxis of venous thromboembolism 2002 SIGN Edinburgh, Scotland
8. Douketis J Hormone replacement therapy and risk for venous thromboembolism: What's new and how do these findings influence clinical practice? Curr Opin Hematol. 12 2005 395-400
9. Walker ID Hormone replacement therapy and venous thromboembolism Thromb Res. 115 Suppl 1 2005 88-92
10. Jick H Derby LE Myers MW et. al. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens Lancet 348 1996 981-983
11. Daly E Vessey MP Hawkins MM et. al. Risk of venous thromboembolism in users of hormone replacement therapy Lancet 348 1996 977-980
12. Grodstein F Stampfer MJ Goldhaber SZ et. al. Prospective study of exogenous hormones and risk of pulmonary embolism in women Lancet 348 1996 983-987
13. Perez Gutthann S Garcia Rodriguez LA Castellsague J Duque Oliart A Hormone replacement therapy and risk of venous thromboembolism: Population based case-control study BMJ 314 1997 796-800
14. Varas-Lorenzo C Garcia-Rodriguez LA Cattaruzzi C et. al. Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: A population-based study in southern Europe Am J Epidemiol 147 1998 387-390
15. for the Heart and Estrogen/progestin Replacement Study Grady D Wenger NK Herrington D et. al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease Ann Intern Med 132 2000 689-696
16. Hoibraaten E Abdelnoor M Sandset PM Hormone replacement therapy with estradiol and risk of venous thromboembolism - a population-based case-control study Thromb Haemost 82 1999 1218-1221
17. for the Women's Health Initiative Investigators Cushman M Kuller LH Prentice R et. al. Estrogen plus progestin and risk of venous thrombosis JAMA 292 2004 1573-1580
18. for the EStrogen and THromboEmbolism Risk Study Group Scarabin PY Oger E Plu-Bureau G Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk Lancet 362 2003 428-432
19. Douketis JD Julian JA Kearon C et. al. Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case-control study J Thromb Haemost 3 2005 943-948
20. for the Women's Health Initiative Steering Committee Anderson GL Limacher M Assaf AR et. al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial JAMA 291 2004 1701-1712
21. Smith NL Heckbert SR Lemaitre RN et. al. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis JAMA 292 2004 1581-1587
22. Haemostasis and Thrombosis Task Force, British Committee for Standards in Haematology Investigation and management of heritable thrombophilia Br J Haematol 114 2001 512-528
23. Koster T Blann AD Briet E et. al. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis Lancet 345 1995 152-155
24. den Heijer M Koster T Blom HJ et. al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis N Engl J Med 334 1996 759-762
25. Clark P Walker ID The phenomenon known as acquired activated protein C resistance Br J Haematol 115 2001 767-773
26. Lowe G Woodward M Vessey M et. al. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years. Relationships to hormone replacement therapy Thromb Haemost 83 2000 530-535
27. Herrington DM Vittinghoff E Howard TD et. al. Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease Arterioscler Thromb Vasc Biol 22 2002 1012-1017
28. [published correction appears in Control Clin Trials. 2000;21:414] Herrington DM Reboussin DM Klein KP et. al. The estrogen replacement and atherosclerosis (ERA) study: Study design and baseline characteristics of the cohort Control Clin Trials 21 2000 257-285
29. Grady D Applegate W Bush T et. al. Heart and Estrogen/progestin Replacement Study (HERS): Design, methods, and baseline characteristics Control Clin Trials 19 1998 314-335
30. Rosendaal FR Vessey M Rumley A et. al. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis Br J Haematol 116 2002 851-854
31. for the Thrombosis Wu O Robertson L Twaddle S et. al. Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Screening for thrombophilia in high-risk situations: A meta-analysis and cost-effectiveness analysis Br J Haematol 131 2005 80-90
32. Lowe GD Upton MN Rumley A et. al. Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein - a cross-sectional population survey Thromb Haemost 86 2001 550-556
33. for the Thrombosis Wu O Robertson L Langhorne P et. al. Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: A systematic review Thromb Haemostat 94 2005 17-25